close 73% inwestorów detalicznych traci pieniądze podczas handlu CFD z tym dostawcą. Inwestowanie wiąże się z ryzykiem i nie jest odpowiednie dla wszystkich inwestorów. Kontrakty CFD są złożonymi instrumentami i wiążą się z dużym ryzykiem szybkiej utraty środków pieniężnych z powodu dźwigni finansowej. 73% rachunków inwestorów detalicznych notuje stratę pieniędzy podczas handlu kontraktami CFD z tym dostawcą. Upewnij się, czy rozumiesz, jak działają kontrakty CFD, i czy możesz pozwolić sobie na wysokie ryzyko utraty pieniędzy.
Change languagePolski
Pulpit

LLY

1,019.16

+2.69%↑

JNJ

210.09

+2.68%↑

ABBV

222.92

-0.29%↓

UNH

339.07

+4.39%↑

AZN

90.72

+0.2%↑

LLY

1,019.16

+2.69%↑

JNJ

210.09

+2.68%↑

ABBV

222.92

-0.29%↓

UNH

339.07

+4.39%↑

AZN

90.72

+0.2%↑

LLY

1,019.16

+2.69%↑

JNJ

210.09

+2.68%↑

ABBV

222.92

-0.29%↓

UNH

339.07

+4.39%↑

AZN

90.72

+0.2%↑

LLY

1,019.16

+2.69%↑

JNJ

210.09

+2.68%↑

ABBV

222.92

-0.29%↓

UNH

339.07

+4.39%↑

AZN

90.72

+0.2%↑

LLY

1,019.16

+2.69%↑

JNJ

210.09

+2.68%↑

ABBV

222.92

-0.29%↓

UNH

339.07

+4.39%↑

AZN

90.72

+0.2%↑

Strona główna・Stock List・Karyopharm Therapeutics Inc
Search

Karyopharm Therapeutics Inc

Open

SectorHealthcare

6.82 6.4

Strong Buy

Price update 11 gru 2025, 18:51 UTC

BuySell

Overview

Share price change

24h

Current

Min

6.09

Max

7

Key metrics

By Trading Economics

Income

4.1M

-33M

Sales

6.1M

44M

EPS

-3.82

Profit margin

-75.213

Employees

279

EBITDA

1.8M

-23M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+116.43% upside

Market Stats

By TradingEconomics

Market Cap

-1.8M

100M

Previous open

0.42

Previous close

6.82

News Sentiment

By Acuity

50%

50%

195 / 374 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Bullish Evidence

5.9501 / 7.66 Support & Resistance

Karyopharm Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

10 gru 2025, 22:02 UTC

Earnings

Synopsys Sees Strong 2026 as Ansys Acquisition Boosts 4Q Revenue

DJ

Read

10 gru 2025, 21:46 UTC

Earnings

Adobe Expects Double-Digit Recurring Revenue Growth Next Year

DJ

Read

10 gru 2025, 23:52 UTC

Acquisitions, Mergers, Takeovers

Paramount Sends Letter to Warner Bros. Shareholders Saying Its Offer Is 'Superior' -- Barrons.com

DJ

Read

10 gru 2025, 23:43 UTC

Market Talk

Nikkei May Rise After Fed Rate Cut -- Market Talk

DJ

Read

10 gru 2025, 23:36 UTC

Market Talk

Gold Consolidates as Traders Digest FOMC Decision -- Market Talk

DJ

Read

10 gru 2025, 23:20 UTC

Earnings

Oracle Reports $16.1 Billion in Revenue, Narrowly Missing Forecasts -- 2nd Update

DJ

Read

10 gru 2025, 23:15 UTC

Earnings

Synopsys Targets Double-Digit Growth Following Ansys Acquisition -- Interview

DJ

Read

10 gru 2025, 22:59 UTC

Market Talk
Earnings
Acquisitions, Mergers, Takeovers

Adobe Expects Semrush Deal to Bring in New Users -- Market Talk

DJ

Read

10 gru 2025, 22:45 UTC

Market Talk

Coca-Cola's New CEO Pick Looks A Lot Like The Last One -- Market Talk

DJ

Read

10 gru 2025, 22:40 UTC

Earnings

Synopsys Stock Rises on Earnings Beat, Higher Guidance -- Barrons.com

DJ

Read

10 gru 2025, 22:06 UTC

Acquisitions, Mergers, Takeovers

Paramount Sends Letter to Warner Bros. Shareholders Saying Their Offer Is 'Superior' -- Barrons.com

DJ

Read

10 gru 2025, 22:06 UTC

Earnings

Oracle Reports Mixed Earnings. The Stock Is Falling. -- Barrons.com

DJ

Read

10 gru 2025, 22:02 UTC

Earnings

Synopsys Stock Rises on Earnings Beat, Higher Guidance -- Barrons.com

DJ

Read

10 gru 2025, 22:00 UTC

Earnings

Oracle Reports $16.1 Billion in Revenue, Narrowly Missing Forecasts -- Update

DJ

Read

10 gru 2025, 21:53 UTC

Earnings

Adobe Earnings Show 'Rapid Adoption' of AI Tools. The Stock Is Up. -- Barrons.com

DJ

Read

10 gru 2025, 21:50 UTC

Acquisitions, Mergers, Takeovers

Investors Bet That a Higher Bid for Warner Is Coming -- Update

DJ

Read

10 gru 2025, 21:50 UTC

Market Talk
Earnings
Acquisitions, Mergers, Takeovers

Financial Services Roundup: Market Talk

DJ

Read

10 gru 2025, 21:50 UTC

Market Talk

Health Care Roundup: Market Talk

DJ

Read

10 gru 2025, 21:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

DJ

Read

10 gru 2025, 21:45 UTC

Acquisitions, Mergers, Takeovers

Paramount Sends Letter to Warner Bros. Shareholders Saying Their Offer Is 'Superior' -- Barrons.com

DJ

Read

10 gru 2025, 21:33 UTC

Earnings

Oracle Reports $16.1 Billion in Revenue, Narrowly Missing Forecasts -- WSJ

DJ

Read

10 gru 2025, 21:32 UTC

Earnings

Oracle Reports Mixed Earnings. The Stock Is Falling. -- Barrons.com

DJ

Read

10 gru 2025, 21:28 UTC

Acquisitions, Mergers, Takeovers

Sverica Capital Management Announces Sale of Coastal Cloud Holdings to Tata Consultancy Services for $700M

DJ

Read

10 gru 2025, 21:25 UTC

Earnings

Adobe Earnings Show 'Rapid Adoption' of AI Tools. The Stock Is Up. -- Barrons.com

DJ

Read

10 gru 2025, 21:18 UTC

Acquisitions, Mergers, Takeovers

Paramount Skydance: Company Has Air Tight Financing to Deliver on Warner Bros. Offer >PSKY

DJ

Read

10 gru 2025, 21:16 UTC

Earnings

Oracle Reports Mixed Earnings. The Stock is Falling. -- Barrons.com

DJ

Read

10 gru 2025, 21:15 UTC

Acquisitions, Mergers, Takeovers

Paramount Skydance: Public Offer for Warner Bros. Delivers Superior Value, Faster, More Certain Path to Completion

DJ

Read

10 gru 2025, 21:15 UTC

Earnings

Oracle: 'Sold Ampere Because We No Longer Think It Is Strategic for Us to Continue Designing, Manufacturing and Using Our Own Chips in Our Cloud Datacenters' >ORCL

DJ

Read

10 gru 2025, 21:14 UTC

Earnings

Oracle 2Q Non-GAAP Operating Income Was $6.7 B >ORCL

DJ

Read

10 gru 2025, 21:14 UTC

Earnings

Oracle 2Q GAAP Operating Income Was $4.7 B >ORCL

DJ

Read

Peer Comparison

Price change

Karyopharm Therapeutics Inc Forecast

Price Target

By TipRanks

116.43% upside

12 Months Forecast

Average 13.83 USD  116.43%

High 21 USD

Low 6 USD

Based on 6 Wall Street analysts offering 12 month price targets forKaryopharm Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

6 ratings

5

Buy

1

Hold

0

Sell

Based on 6 analysts giving stock ratings to Karyopharm Therapeutics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

5.9501 / 7.66Support & Resistance

Short Term

Bullish Evidence

Recent bullish events outweigh bearish events.

Intermediate Term

Strong Bearish Evidence

All events are bearish.

Long Term

No Evidence

There are no events.

Sentiment

By Acuity

195 / 374 Ranking in Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

Other stocks from the sector

LLY

Eli Lilly and Co.

1,019.16

↑ +2.69%

JNJ

Johnson and Johnson

210.09

↑ +2.68%

ABBV

AbbVie Inc

222.92

↓-0.29%

UNH

UnitedHealth Group Inc

339.07

↑ +4.39%

AZN

AstraZeneca PLC ADR

90.72

↑ +0.2%
help-icon Live chat